Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Avidity Biosciences (RNA) Profit After Tax (2019 - 2025)

Historic Profit After Tax for Avidity Biosciences (RNA) over the last 7 years, with Q3 2025 value amounting to -$174.4 million.

  • Avidity Biosciences' Profit After Tax fell 11697.31% to -$174.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$549.8 million, marking a year-over-year decrease of 9601.02%. This contributed to the annual value of -$322.3 million for FY2024, which is 5187.16% down from last year.
  • Avidity Biosciences' Profit After Tax amounted to -$174.4 million in Q3 2025, which was down 11697.31% from -$157.3 million recorded in Q2 2025.
  • Over the past 5 years, Avidity Biosciences' Profit After Tax peaked at -$23.8 million during Q1 2021, and registered a low of -$174.4 million during Q3 2025.
  • Over the past 5 years, Avidity Biosciences' median Profit After Tax value was -$52.4 million (recorded in 2023), while the average stood at -$67.1 million.
  • Its Profit After Tax has fluctuated over the past 5 years, first tumbled by 29184.88% in 2021, then tumbled by 292.19% in 2023.
  • Quarter analysis of 5 years shows Avidity Biosciences' Profit After Tax stood at -$38.5 million in 2021, then tumbled by 30.96% to -$50.5 million in 2022, then dropped by 19.76% to -$60.4 million in 2023, then plummeted by 69.18% to -$102.3 million in 2024, then plummeted by 70.59% to -$174.4 million in 2025.
  • Its Profit After Tax was -$174.4 million in Q3 2025, compared to -$157.3 million in Q2 2025 and -$115.8 million in Q1 2025.